PE20180232A1 - Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue - Google Patents

Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue

Info

Publication number
PE20180232A1
PE20180232A1 PE2017002377A PE2017002377A PE20180232A1 PE 20180232 A1 PE20180232 A1 PE 20180232A1 PE 2017002377 A PE2017002377 A PE 2017002377A PE 2017002377 A PE2017002377 A PE 2017002377A PE 20180232 A1 PE20180232 A1 PE 20180232A1
Authority
PE
Peru
Prior art keywords
mono
dengue
disustituted
indol
inhibitors
Prior art date
Application number
PE2017002377A
Other languages
English (en)
Inventor
Bart Rudolf Romanie Kesteleyn
Jean François BONFANTI
Tim Hugo Maria Jonckers
Pierre Jean Marie Bernard Raboisson
Dorothee Alice Marie Eve Bardiot
Arnaud Didier M Marchand
Original Assignee
Janssen Pharmaceuticals Inc
Univ Leuven Kath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceuticals Inc, Univ Leuven Kath filed Critical Janssen Pharmaceuticals Inc
Publication of PE20180232A1 publication Critical patent/PE20180232A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Referido a un compuesto de formula (I), donde: R1 es H, CH3, OCF3 entre otros; R2 es F, H OCH3 entre otros y R3 es H o CH3. Este compuesto se refiere a un grupo indol mono o disustituido, que tiene una forma estereo isomerica, una sal, solvato o polimorfo farmaceuticamente aceptable. Dichos compuestos se usan para inhibir la replicacion del virus del dengue. Tambien se refiere preparaciones de composiciones para su uso como medicamento para la prevencion o tratamiento de infecciones virales por dengue.
PE2017002377A 2015-05-08 2016-05-04 Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue PE20180232A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15166900 2015-05-08
EP16163342 2016-03-31

Publications (1)

Publication Number Publication Date
PE20180232A1 true PE20180232A1 (es) 2018-01-31

Family

ID=56026812

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2017002377A PE20180232A1 (es) 2015-05-08 2016-05-04 Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue
PE2021001440A PE20221579A1 (es) 2015-05-08 2016-05-04 Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2021001440A PE20221579A1 (es) 2015-05-08 2016-05-04 Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue

Country Status (38)

Country Link
US (3) US10696632B2 (es)
EP (2) EP3294738B1 (es)
JP (4) JP6752821B2 (es)
KR (2) KR102610493B1 (es)
CN (3) CN113045476A (es)
AU (2) AU2016259677B2 (es)
BR (1) BR112017023904A2 (es)
CA (1) CA2981845C (es)
CL (1) CL2017002817A1 (es)
CO (1) CO2017012381A2 (es)
CR (2) CR20200152A (es)
CY (1) CY1124548T1 (es)
DK (1) DK3294738T3 (es)
EA (1) EA034978B1 (es)
EC (2) ECSP17073878A (es)
ES (2) ES2877404T3 (es)
GT (1) GT201700234A (es)
HK (2) HK1252446A1 (es)
HR (1) HRP20210675T1 (es)
HU (1) HUE054724T2 (es)
IL (2) IL255430B (es)
JO (2) JOP20160086B1 (es)
LT (1) LT3294738T (es)
MD (1) MD3294738T2 (es)
MX (2) MX2017014293A (es)
NI (1) NI201700137A (es)
PE (2) PE20180232A1 (es)
PH (1) PH12017502000B1 (es)
PL (1) PL3294738T3 (es)
RS (1) RS62029B1 (es)
SG (1) SG10201900315SA (es)
SI (1) SI3294738T1 (es)
SV (1) SV2017005557A (es)
TW (2) TWI744963B (es)
UA (1) UA121332C2 (es)
UY (2) UY36674A (es)
WO (1) WO2016180696A1 (es)
ZA (1) ZA202002435B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
JOP20160086B1 (ar) 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3436435B1 (en) 2016-03-31 2021-05-12 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
MX2018011788A (es) 2016-03-31 2019-05-20 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
MA44502A (fr) * 2016-04-01 2019-02-06 Janssen Pharmaceuticals Inc Dérivés d'indole substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JP7179773B2 (ja) 2017-05-22 2022-11-29 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての置換インドリン誘導体
KR102625988B1 (ko) 2017-05-22 2024-01-16 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체
EP4058019A1 (en) 2019-11-15 2022-09-21 Janssen Pharmaceuticals, Inc. Treatment and prevention of dengue disease
WO2022094817A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Pharmaceutical formulation
WO2022094816A1 (en) 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Solid formulation
CN113024440B (zh) * 2021-03-17 2023-05-16 凯莱英医药集团（天津）股份有限公司 连续化合成取代吲哚-2-羧酸的方法
KR20240027735A (ko) 2021-06-29 2024-03-04 얀센 파마슈티칼즈, 인코포레이티드 (s)-2-(4-클로로-2-메톡시페닐)-2-((3-메톡시-5-(메틸설포닐)페닐)아미노)-1-(1h-인돌-3-일)에테논유도체의 제조 방법
WO2023218285A1 (en) 2022-05-12 2023-11-16 Janssen Pharmaceuticals, Inc. Treatment or prevention of dengue viral infection
CN115521307B (zh) * 2022-09-30 2023-09-22 甘肃皓天医药科技有限责任公司 一种5-卤代-7-氮杂吲哚的制备方法

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE296286T1 (de) 1997-10-27 2005-06-15 Lilly Co Eli Morpholino-n-ethyl ester prodrogen von indol spla 2 hemmer
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
JP2005520795A (ja) 2001-12-12 2005-07-14 コンフォーマ・セラピューティクス・コーポレイション Ｈｓｐ９０阻害活性を有するプリン類似体
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
US20060211698A1 (en) 2005-01-14 2006-09-21 Genelabs, Inc. Bicyclic heteroaryl derivatives for treating viruses
AU2006221080A1 (en) 2005-02-09 2006-09-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
US9029376B2 (en) 2008-06-03 2015-05-12 Siga Technologies, Inc. Small molecule inhibitors for the treatment or prevention of dengue virus infection
US20120040974A1 (en) * 2008-08-18 2012-02-16 Yale University Mif modulators
JP5559174B2 (ja) 2008-08-19 2014-07-23 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 冷感−メントール受容体拮抗剤
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
EP2393359A4 (en) 2009-02-09 2012-10-03 Enanta Pharm Inc COMPOUND DIBENZIMIDAZOLE DERIVATIVES
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
CA2785563C (en) 2010-01-15 2019-05-14 Gilead Sciences, Inc. Inhibitors of flaviviridae viruses
EP2552211A4 (en) 2010-03-26 2013-10-23 Glaxo Group Ltd INDAZOLYL-PYRIMIDINE AS KINASEHEMMER
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201116559D0 (en) * 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
WO2015059212A1 (en) 2013-10-23 2015-04-30 Janssen R&D Ireland Carboxamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
TWI688564B (zh) 2014-01-31 2020-03-21 美商必治妥美雅史谷比公司 作為凝血因子ｘｉａ抑制劑之具有雜環p2'基團之巨環化合物
WO2015187815A1 (en) 2014-06-04 2015-12-10 Fred Hutchinson Cancer Research Center Expansion and engraftment of stem cells using notch 1 and/or notch 2 agonists
BR112016028285B1 (pt) 2014-06-04 2023-02-23 Amgen Inc Método para uma colheita periódica prolongada, sistema de filtro de unidade única e método para cultivo de células que expressam proteína recombinante
WO2016050841A1 (en) 2014-10-01 2016-04-07 Janssen Pharmaceuticals, Inc. Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
PL3201177T3 (pl) 2014-10-01 2019-05-31 Janssen Pharmaceuticals Inc Mono- lub di-podstawione indole jako inhibitory replikacji wirusa dengi
NO2721243T3 (es) 2014-10-01 2018-10-20
BR112017007229A2 (pt) 2014-10-10 2021-02-09 Rutgers, The State University Of New Jersey primers de reação de cadeia de polimerase e sondas para mycobacterium tuberculosis
JOP20150335B1 (ar) * 2015-01-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA2992825C (en) 2015-07-22 2021-05-04 Omeicos Therapeutics Gmbh Metabolically robust analogs of cyp-eicosanoids for the treatment of cardiac disease
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
BR112018009010B1 (pt) 2015-11-03 2023-09-26 Zoetis Services Llc Uso de um compósito polimérico de sol-gel para prevenir ou tratar mastite em um mamífero não humano fêmea que tem um período de lactação e sistema para formar uma barreira física no canal ou cisterna da teta do dito mamífero
EP3436435B1 (en) 2016-03-31 2021-05-12 Janssen Pharmaceuticals, Inc. Substituted indole derivatives as dengue viral replication inhibitors
MX2018011788A (es) 2016-03-31 2019-05-20 Janssen Pharmaceuticals Inc Derivados de indolina sustituidos como inhibidores de la replicacion virica de dengue.
TWI738753B (zh) 2016-03-31 2021-09-11 日商武田藥品工業股份有限公司 雜環化合物
JP2019516352A (ja) 2016-04-01 2019-06-20 アムジエン・インコーポレーテツド Ｆｌｔ３に対するキメラ受容体及びその使用方法
ES2930058T3 (es) 2016-04-01 2022-12-05 Kite Pharma Inc Receptores quiméricos y métodos de uso de los mismos
CN108779121A (zh) 2016-04-01 2018-11-09 巴斯夫欧洲公司 双环化合物
BR112018070073A2 (pt) 2016-04-01 2019-02-12 Kite Pharma, Inc. receptores de antígeno quimérico e célula t e métodos de uso
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
US10576085B2 (en) 2016-04-01 2020-03-03 Signal Pharmaceuticals, Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
MA44502A (fr) 2016-04-01 2019-02-06 Janssen Pharmaceuticals Inc Dérivés d'indole substitués utilisés en tant qu'inhibiteurs de réplication du virus de la dengue
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
KR102625988B1 (ko) 2017-05-22 2024-01-16 얀센 파마슈티칼즈, 인코포레이티드 뎅기 바이러스 복제 억제제로서의 치환 인돌린 유도체
JP7179773B2 (ja) 2017-05-22 2022-11-29 ヤンセン ファーマシューティカルズ，インコーポレーテッド デングウイルス複製阻害剤としての置換インドリン誘導体

Also Published As

Publication number Publication date
PE20221579A1 (es) 2022-10-06
CR20170490A (es) 2018-03-08
ECSP22023220A (es) 2022-05-31
CR20200152A (es) 2020-09-08
HRP20210675T1 (hr) 2021-06-25
KR102610493B1 (ko) 2023-12-05
SG10201900315SA (en) 2019-02-27
US20210171462A1 (en) 2021-06-10
AU2016259677A1 (en) 2017-10-26
CN107873022B (zh) 2021-03-12
ZA202002435B (en) 2023-03-29
UY39706A (es) 2022-05-31
SI3294738T1 (sl) 2021-08-31
IL272814B (en) 2021-02-28
GT201700234A (es) 2018-11-26
CN111303000A (zh) 2020-06-19
KR102610491B1 (ko) 2023-12-06
EA201792429A1 (ru) 2018-02-28
BR112017023904A2 (pt) 2018-07-17
DK3294738T3 (da) 2021-06-28
AU2016259677B2 (en) 2020-10-01
JP2018515495A (ja) 2018-06-14
NI201700137A (es) 2019-05-07
JOP20210109A1 (ar) 2023-01-30
CL2017002817A1 (es) 2018-05-11
CA2981845C (en) 2022-03-08
KR20180002644A (ko) 2018-01-08
CN113045476A (zh) 2021-06-29
WO2016180696A1 (en) 2016-11-17
JOP20160086B1 (ar) 2021-08-17
PH12017502000A1 (en) 2018-03-26
HUE054724T2 (hu) 2021-09-28
MX2020011156A (es) 2022-04-21
EP3294738B1 (en) 2021-04-07
US20180346419A1 (en) 2018-12-06
IL255430B (en) 2020-03-31
IL255430A0 (en) 2017-12-31
ES2941674T3 (es) 2023-05-24
TWI725969B (zh) 2021-05-01
LT3294738T (lt) 2021-08-25
TW201704208A (zh) 2017-02-01
EP3896072A1 (en) 2021-10-20
ES2877404T3 (es) 2021-11-16
JP7132399B2 (ja) 2022-09-06
CA2981845A1 (en) 2016-11-17
UY36674A (es) 2016-11-30
TW202041499A (zh) 2020-11-16
PH12017502000B1 (en) 2018-03-26
ECSP17073878A (es) 2018-02-28
KR20210048578A (ko) 2021-05-03
HK1252446A1 (zh) 2019-05-24
JP2021138752A (ja) 2021-09-16
JP7451626B2 (ja) 2024-03-18
EP3294738A1 (en) 2018-03-21
MX2017014293A (es) 2018-08-09
EP3896072B1 (en) 2022-11-16
AU2020273314A1 (en) 2020-12-17
US10919854B2 (en) 2021-02-16
HK1252496A1 (zh) 2019-05-31
PL3294738T3 (pl) 2021-12-13
EA034978B1 (ru) 2020-04-14
CN107873022A (zh) 2018-04-03
IL272814A (en) 2020-04-30
US11827602B2 (en) 2023-11-28
MD3294738T2 (ro) 2021-08-31
CO2017012381A2 (es) 2018-03-28
JP2022166289A (ja) 2022-11-01
AU2020273314B2 (en) 2021-10-21
SV2017005557A (es) 2018-06-26
CN111303000B (zh) 2023-11-28
US20200270209A1 (en) 2020-08-27
CY1124548T1 (el) 2022-07-22
JP6898493B2 (ja) 2021-07-07
US10696632B2 (en) 2020-06-30
NZ736934A (en) 2023-11-24
JP6752821B2 (ja) 2020-09-09
TWI744963B (zh) 2021-11-01
JP2020125316A (ja) 2020-08-20
UA121332C2 (uk) 2020-05-12
RS62029B1 (sr) 2021-07-30

Similar Documents

Publication Publication Date Title
PE20180232A1 (es) Derivados de indol mono o disustituidos como inhibidores de la replicacion viral del dengue
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
DOP2019000201A (es) Compuestos inhibidores del vih
CO2020004301A2 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih
CL2020001218A1 (es) Compuestos útiles para inhibir a cdk7.
CL2017000742A1 (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
CL2018000697A1 (es) Derivados de indol mono - o disustituidos como inhibidores de la replicación viral del dengue.
EA201790758A1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге
CL2017001822A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
EA201892200A1 (ru) Замещенные производные соединений индола в качестве ингибиторов репликации вирусов денге
EA201892216A1 (ru) Замещенные производные индолина в качестве ингибиторов репликации вирусов денге
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
AR111314A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
AR111820A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación de virus del dengue
CR20180495A (es) Deribados de indol sustituidos como inhibidores de replicación viral del dengue
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
EA201890722A1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге
CU24434B1 (es) Compuestos derivados de n-(1,5-dimetil-3-oxo-2,3-dihidro-1h-pirazol-4-il)-4-metil-5-isoxazol-3-carboxamida activos como inhibidores selectivos de smurf-1
AR120158A2 (es) Derivados de indol mono o di sustituidos como inhibidores de la replicación viral del dengue
AR102135A1 (es) Indoles mono o disustituidos como inhibidores de la replicación del virus del dengue
AR113817A1 (es) Compuestos útiles para inhibir a cdk7
AR106029A1 (es) Derivados de indol mono- o disustituidos como inhibidores de la replicación viral del dengue
AR109850A2 (es) Métodos para tratar infecciones por el virus filoviridae